Back to search

Belgium· BE-AMP-SAM663912-00

Omvoh 100 mg - 200 mg

A mirikizumab product containing mirikizumab, registered in Belgium by Eli Lilly Nederland. The same ATC class is registered in 13 of our 19 countries.

ATC L04AC24

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedOmvoh 100 mg - 200 mgATCL04AC24REGISTER NO.BE-AMP-SAM663912-00PACKS LISTED2CHECKEDSeptember 26, 2026

Where it is registered

Mirikizumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L04AC24 (mirikizumab), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Mirikizumab · ATC L04AC24

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mirikizumab costs, country by country.

Normalised to the WHO defined daily dose (7.1 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Mirikizumab · price per daily dose (7.1 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$30.99
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Mirikizumab
Manufacturer
Eli Lilly Nederland
Country
Belgium (BE)
ATC code
L04AC24
ATC class
Mirikizumab
Defined daily dose
7.1 mg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

1 priced
  • be_apb
    4987012
    EUR 3027.73
  • be_apb
    7747645

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/da0f71b2-a726-46b5-bd1e-8cd3464c2182
GET /v1/drugs/da0f71b2-a726-46b5-bd1e-8cd3464c2182?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled syringe",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Omvoh 100 mg - 200 mg",
  "name_fr": "Omvoh 100 mg - 200 mg",
  "name_nl": "Omvoh 100 mg - 200 mg",
  "amp_code": "SAM663912-00",
  "strengths": [
    "200.0000",
    "200.0000",
    "100.0000",
    "100.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Mirikizumab",
    "Mannitol",
    "Sodium Chloride",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Mirikizumab",
  "authorisation_numbers": [
    "EU/1/23/1736/008",
    "EU/1/23/1736/007"
  ]
}

See everything about mirikizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.